JP2528706B2 - ジヒドロピリジン化合物の製剤組成物 - Google Patents

ジヒドロピリジン化合物の製剤組成物

Info

Publication number
JP2528706B2
JP2528706B2 JP1050471A JP5047189A JP2528706B2 JP 2528706 B2 JP2528706 B2 JP 2528706B2 JP 1050471 A JP1050471 A JP 1050471A JP 5047189 A JP5047189 A JP 5047189A JP 2528706 B2 JP2528706 B2 JP 2528706B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ethanol
cellulose
solution
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP1050471A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0249728A (ja
Inventor
勝春 宮嶋
幸也 山口
隆男 常松
寿久 織田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Original Assignee
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP1050471A priority Critical patent/JP2528706B2/ja
Application filed by Zeria Pharmaceutical Co Ltd, Nissan Chemical Corp filed Critical Zeria Pharmaceutical Co Ltd
Priority to AT89109381T priority patent/ATE68699T1/de
Priority to ES89109381T priority patent/ES2051920T3/es
Priority to EP89109381A priority patent/EP0344603B1/en
Priority to DE8989109381T priority patent/DE68900356D1/de
Priority to CA000600631A priority patent/CA1332152C/en
Priority to NZ229309A priority patent/NZ229309A/en
Priority to US07/358,144 priority patent/US4983593A/en
Publication of JPH0249728A publication Critical patent/JPH0249728A/ja
Priority to GR920400057T priority patent/GR3003615T3/el
Application granted granted Critical
Publication of JP2528706B2 publication Critical patent/JP2528706B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP1050471A 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物 Expired - Lifetime JP2528706B2 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP1050471A JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物
ES89109381T ES2051920T3 (es) 1988-05-30 1989-05-24 Una composicion farmaceutica y su procedimiento de preparacion.
EP89109381A EP0344603B1 (en) 1988-05-30 1989-05-24 Pharmaceutical composition of dihydropyridine compound
DE8989109381T DE68900356D1 (de) 1988-05-30 1989-05-24 Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.
AT89109381T ATE68699T1 (de) 1988-05-30 1989-05-24 Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.
CA000600631A CA1332152C (en) 1988-05-30 1989-05-25 Pharmaceutical composition of dihydropyridine compound
NZ229309A NZ229309A (en) 1988-05-30 1989-05-26 Pharmaceutical composition comprising a 1,4-dihydropyridine-5-phosphonic acid derivative and hydroxypropylmethyl cellulose acetate
US07/358,144 US4983593A (en) 1988-05-30 1989-05-30 Pharmaceutical composition of dihydropyridine compound
GR920400057T GR3003615T3 (enExample) 1988-05-30 1992-01-22

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP13226288 1988-05-30
JP63-132262 1988-05-30
JP1050471A JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物

Publications (2)

Publication Number Publication Date
JPH0249728A JPH0249728A (ja) 1990-02-20
JP2528706B2 true JP2528706B2 (ja) 1996-08-28

Family

ID=26390939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1050471A Expired - Lifetime JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物

Country Status (8)

Country Link
US (1) US4983593A (enExample)
EP (1) EP0344603B1 (enExample)
JP (1) JP2528706B2 (enExample)
CA (1) CA1332152C (enExample)
DE (1) DE68900356D1 (enExample)
ES (1) ES2051920T3 (enExample)
GR (1) GR3003615T3 (enExample)
NZ (1) NZ229309A (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212139B (enExample) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
AU1941897A (en) 1996-03-18 1997-10-10 Nissan Chemical Industries Ltd. Process for producing efonidipine hydrochloride preparations
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6350786B1 (en) † 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US7078057B2 (en) * 1999-12-20 2006-07-18 Kerkhof Nicholas J Process for producing nanometer particles by fluid bed spray-drying
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
WO2005115330A2 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US20080096924A1 (en) * 2004-12-17 2008-04-24 Ono Pharmaceutical Co., Ltd. Amorphous Composition
CA2621800A1 (en) * 2005-09-06 2007-03-15 Astellas Pharma Inc. Fine particles of poorly soluble drug having enteric base material adsorbed on the surface thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
WO2009072334A1 (ja) * 2007-12-03 2009-06-11 Tomita Pharmaceutical Co., Ltd. 製剤用核粒子
US20110065800A1 (en) * 2008-05-14 2011-03-17 Haihong Fan Formulations for cathepsin k inhibitors
MX2011008303A (es) 2009-04-03 2011-11-29 Plexxikon Inc Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas.
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
BR112012031667A2 (pt) 2010-06-14 2016-11-08 Dow Global Technologies Llc composição
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8591944B2 (en) 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CA2935307C (en) 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
US20190030003A1 (en) * 2017-03-21 2019-01-31 Bioduro, Llc Gastrointestinal-protective formulations for oral delivery of proteins and peptides
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
WO2021127452A1 (en) 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948810A (ja) 1982-09-10 1984-03-21 Sony Corp 磁性記録体におけるデ−タのマスク及び再生方法
JPS62123117A (ja) 1985-11-22 1987-06-04 Nippon Chemiphar Co Ltd 塩酸ニカルジピン経口用組成物
CN1016063B (zh) * 1986-01-22 1992-04-01 日产化学工业株式会社 二氢吡啶-5-膦酸环亚丙基酯的制备
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation

Also Published As

Publication number Publication date
CA1332152C (en) 1994-09-27
GR3003615T3 (enExample) 1993-03-16
ES2051920T3 (es) 1994-07-01
EP0344603B1 (en) 1991-10-23
DE68900356D1 (de) 1991-11-28
EP0344603A1 (en) 1989-12-06
US4983593A (en) 1991-01-08
JPH0249728A (ja) 1990-02-20
NZ229309A (en) 1991-06-25

Similar Documents

Publication Publication Date Title
JP2528706B2 (ja) ジヒドロピリジン化合物の製剤組成物
US4673564A (en) Sustained release pharmaceutical composition of solid medical material
US20250288681A1 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
KR101454086B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
NZ502062A (en) Process for manufacturing paroxetine solid dispersions
AU2020276701B2 (en) Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
JP2008280352A (ja) 溶解性または経口吸収性の改善された組成物
IL182647A (en) Oral preparation with bioavailability
JP2002513760A (ja) パロキセチン固体分散体を製造するための水系方法
US20240173310A1 (en) Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
EP2714676B1 (en) A process for the preparation of polymorphic form i of etoricoxib
JP2000514057A (ja) 増強されたバイオアベイラビリティを有する抗真菌剤の固溶体
ES2377552T3 (es) Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda
WO2012159511A1 (zh) 阿齐沙坦固体分散体及其制备方法和药物组合物
JPH04360833A (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
JP2023502011A (ja) レバムロジピンベシル酸塩水和物含有組成物及びその調製方法
WO2004101561A1 (en) Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20090030057A1 (en) Pharmaceutical composition of telmisartan
SK11632003A3 (sk) Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu
JP4608087B2 (ja) 固形製剤の製造法
US20080255231A1 (en) Polymorphs of rivastigmine hydrogentartrate
JPH0776516A (ja) 難溶性薬物含有製剤の製造方法
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
WO2024136768A1 (en) Stable pharmaceutical compositions comprising amorphous tolvaptan
WO2025051851A1 (en) Pharmaceutical dosage forms comprising 2-(2-chlorophenyl)-n-[4-(4-cyano-1h-pyrazol-1-yl)-3-sulfamoylphenyl]acetamide

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080614

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090614

Year of fee payment: 13

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090614

Year of fee payment: 13